Exagen Inc. (XGN) is a Healthcare stock trading at $7.59 (as of 2026-08-25), with a market capitalization of $183.49M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Exagen Inc. develops and markets diagnostic testing products under the AVISE brand based on its cell-bound complement activation technology. Its assays support rheumatology use cases including diagnosis, prognosis, and monitoring for autoimmune and autoimmune-related conditions, such as connective tissue diseases, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome, and vasculitis, through multiple AVISE test panels.
Understand Exagen Inc.: how it makes money
Exagen sells blood-based diagnostic tests (the AVISE CTD) to rheumatology labs and payers, enabling diagnosis and monitoring of autoimmune diseases like lupus and rheumatoid arthritis. Revenue comes from test volume and pharma services, with pricing power tied to the scarcity of a complement-based differential diagnostic.
Revenue is a three-lever product: more ordering clinicians times more tests per clinician times a rising price per test, all compounding on a 61% gross-margin base with no close substitute in complement-based CTD diagnostics.
Business quality (Weak): A 16% revenue-growth business with real gross margin (61%) still operating at a loss (operating margin around -9%). The moat is narrow but genuine; the question is whether volume and pricing gains can outpace fixed costs before cash runs thin.
Bull case
Clinician base expanding 15% annually: Management cites 15% clinician growth and improved territory productivity in Q1 FY26. Each new ordering rheumatologist adds recurring test volume, compounding revenue at the company's 61% gross margin base.
Myositis test opens an adjacent space: A myositis diagnostic launch is targeted for early 2027, addressing what management calls a frequently requested need. This extends AVISE beyond current CTD indications into another autoimmune category without requiring a new platform.
Pharma services add a $5M backlog: Pharma services backlog exceeds $5 million with expected realization over two to three years, providing a slower but steadier revenue stream that diversifies income away from pure test-volume swings.
Bear case
Thin volume base, big single events: Winter storms cut testing volume by roughly one-third for two weeks in Q1, and lost tests are not expected to return. Northwell is also unlikely to restore its client-bill arrangement, so one weather system or one lost site can swing a quarter meaningfully.
Collections timing stays unpredictable: Management notes prior-period collections are lumpy and difficult to project, and the current revenue-cycle strategy temporarily increases receivables and cash use. For a company still burning cash at the operating level, when money actually arrives matters as much as how much.
Operating loss still 9% of revenue: The company posted an operating margin of -9% against a 61% gross margin, meaning selling, G&A, and R&D costs exceed what tests generate. Sustained volume and pricing gains are needed to close that gap before the cash buffer thins.